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BACKGROUND AND AIMS: Gemcitabine is the standard therapy for patients with pancreatic cancer with
metastatic disease. Patients with metastatic pancreatic cancer presenting with increased values of C-reactive
protein do not respond to gemcitabine. So far, no studies have evaluated the correlation between chronic
pancreatitis, systemic inflammatory response syndrome, and the loss of chemotherapeutic benefit. METHODS:
Pdx-1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice were assigned into four groups: 1) Sixteen animals received a
daily intraperitoneal injection of caerulein from their ninth week of life on. 2) Sixteen mice were additionally given
gemcitabine. 3) Twelve animals received gemcitabine only. 4) Saline-treated control group. Furthermore, human
Paca44 pancreatic ductal adenocarcinoma cells were seeded and cultured in 0.5% FBS containing growth
medium plus/minus 1 μM gemcitabine plus/minus recombinant human interleukin (IL)-6. RESULTS: Induced
systemic inflammatory response syndrome and a mild chronic pancreatitis diminished the beneficial effects of
gemcitabine upon median overall survival. In median, the monogemcitabine group survived 191 days, whereas
the caerulein-mono group survived 114, the control group 121, and the caerulein gemcitabine group 127 days
(P b .05). In vitro, the induction of STAT3 phosphorylation by recombinant human IL-6 promoted pancreatic ductal
adenocarcinoma cell survival during gemcitabine treatment. CONCLUSION: We could demonstrate for the first
time that an improvement in median overall survival with gemcitabine is significantly abolished by a persistent mild
chronic pancreatitis and a systemic inflammatory response syndrome. In particular, the inflammation biomarkers
C-reactive protein, IL-6, and IL-1α could indicate the prognostic benefit of gemcitabine chemotherapy and should
now be tested in prospective patient-controlled trials.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause
of cancer deaths [1]. Unfortunately, the majority of patients presenting
with the disease are already in an unresectable state at the time of
diagnosis due to locally advanced or metastatic spread. Gemcitabine
became the reference regimen for advanced pancreatic cancer after a
randomized trial showed significant improvement in the median overall
survival as compared with fluorouracil administered as an intravenous
bolus (5.6 vs 4.4 months, P = .002) [2]. Numerous phase 3 trials of
gemcitabine in combination with different cytotoxic or molecularly
targeted agents have resulted in no substantial clinical improvement
over the use of gemcitabine alone [3–8]. Only the addition of erlotinib
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overall survival [9]. Last year, Conroy et al., demonstrated that a
combination chemotherapy regimen consisting of oxaliplatin, irinote-
can, fluorouracil, and leucovorin (FOLFIRINOX) as compared with
gemcitabine as first-line therapy in patients with metastatic pancreatic
cancer was associated with a survival advantage but had increased
toxicity [10]. Still, the prognosis remains lethal. The efficacy of
chemotherapy is still poor, and in some patients, systemic condition
rapidly deteriorates after chemotherapeutic failure.
A systemic inflammatory response syndrome, marked by elevated
circulating concentrations of multiple cytokines such as interleukin-6
(IL-6) or C-reactive protein (CRP), has been shown to be a disease-
independent prognostic factor in a variety of tumors [11,12]. CRP is
produced by the liver and is induced by proinflammatory cytokines,
such as IL-6 or tumor necrosis factor-α [13], which are involved in
cachexia. An elevated CRP concentration has previously been shown
to have independent prognostic value in patients with PDAC [14,15].
So far, the mechanisms behind these observed phenomena are neither
known nor analyzed.
Signal transducer and activator of transcription (STAT) proteins
are present in the cytoplasm under basal conditions and are activated
by phosphorylation on a single tyrosine residue. Activation of
STAT3 depends on the phosphorylation of a tyrosine residue by
upstream kinases, such as Janus kinase 2. Janus kinase 2 activation
itself requires activation of the ubiquitin pathway by specific ligands,
e.g., different interleukins. Of these ligands, IL-6 is one of the
strongest activators of STAT3 [16]. STAT3 has been identified as a
key oncogenic factor in a number of epithelial malignancies and is
required for oncogenesis in mouse models of skin and gastric cancers
[17,18]. In the pancreas, STAT3 is dispensable for normal
development, whereas the majority of PDAC show constitutive
activation of STAT3 [19].
The question remains what is the reason for patients being
refractory to gemcitabine chemotherapy who present elevated CRP
levels reflecting a systemic inflammatory immune response syndrome.
In this study, we used a genetically engineered mouse model of PDAC
which recapitulates human invasive pancreatic cancer on a genetic
and histomorphologic level to address this question. We now show
for the first time that gemcitabine will not have any effect on survival
if a mild chronic pancreatitis and a consecutive systemic inflammatory
response are induced in mice during chemotherapy. Furthermore, we
found that IL-6 activates p-STAT3 which leads to increased
chemoresistance in PDAC cells.
Material and Methods
Mice
Conditional LSL-Trp53R172H [20], LSL-KrasG12D, and Pdx1-Cre
[21] strains were interbred to obtain LSL-KrasG12D;LSL-Trp53R172H;
Pdx1-Cre triple-mutant animals on a mixed 129/SvJae/C57Bl/6
background as previously described [22]. All mice were generated
from the same initial stock. All experiments were approved by the local
committees for animal care and use. Animals were maintained in a
climate-controlled room kept at 22°C, exposed to a 12:12-hour light–
dark cycle, fed standard laboratory chow, and given water ad libitum.
Genotyping
For genotyping, genomic DNA was extracted from tail cuttings
using the REDExtract-N-Amp Tissue polymerase chain reaction(PCR) kit (Sigma-Aldrich, St. Louis, MO). Three PCRs were carried
out for each animal to test for the presence of the oncogenic Kras
(using LoxP primers), p53, and Pdx1-Cre transgene constructs
(using Cre-specific primers along with Gabra as positive
control), respectively.
Drug Treatment
Transgenic Pdx-1-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ mice
were randomly assigned into four groups: 1) To induce a chronic
pancreatitis and a consecutive systemic inflammatory response
syndrome, 16 animals received a daily intraperitoneal injection of
5 μg caerulein from their ninth week of life until death. 2) Sixteen
mice were additionally given 2.5 mg gemcitabine weekly from their
13th week of life until death. 3) Twelve animals received only
gemcitabine from their 13th week of life until death. 4) In addition, a
saline-treated group was performed as control (n = 16) (Figure 1). In
cases where littermates were available for drug treatment, only the first
mouse was randomly assigned to one of the three given treatment
groups, the second littermate was then assigned to the “matched”
control arm, and so forth to obtain the highest possible degree of
consistency and to avoid randomization bias as far as possible. All
mice were treated until they developed abdominal distension,
reflecting the accumulation of hemorrhagic ascites, typically
occurring within 48 to 72 hours before death [23].
Histologic Evaluation
After completion of drug treatment, mice were euthanized, blood
was collected from the thoracic cavity for serum analysis, and pancreas
and liver were removed and inspected for grossly visible tumors and
metastases, and both were preserved in 10% formalin solution
(Sigma-Aldrich) for histology and processed for RNA extraction (see
below). Formalin-fixed, paraffin-embedded tissues were sectioned
(4 μm) and stained with hematoxylin and eosin (H&E). Six sections
(100 μm apart) of pancreatic and liver tissues were histologically
evaluated. LSL-KrasG12D;LSL-Trp53R172H;Pdx1-Cre mice were clas-
sified by having developed invasive pancreatic cancer or not.
Immunostaining
For immunolabeling, formalin-fixed and paraffin-embedded
archived tumor samples and corresponding normal tissues were
stained as previously described [22]. Concentrations and sources of
primary antibodies are available on request. Briefly, slides were heated
to 60°C for 1 hour, deparaffinized using xylene, and hydrated by a
graded series of ethanol washes. Antigen retrieval was accomplished
by microwave heating in 10-mM sodium citrate buffer, pH 6.0, for
10 minutes. For immunohistochemistry, endogenous peroxidase
activity was quenched by 10-minute incubation in 3% H2O2.
Nonspecific binding was blocked with 10% serum. Sections were
then incubated with primary antibodies overnight at 4°C. For
immunohistochemistry, bound antibodies were detected using the
avidin–biotin complex (ABC) peroxidase method (ABC Elite Kit,
Vector Labs, Burlingame, CA). Final staining was developed with the
Sigma FAST DAB peroxidase substrate kit (Sigma, Deisenhofen,
Germany). Masson’s trichrome was used to visualize the extracellular
matrix (blue) (10×). The immunohistochemistry results were scored
as described previously [24]: negative = less than 5% cells positive; + =
b30% cells positive; ++ = N30% cells positive. Positive cells
were counted by manual assessment within defined 10× fields of
view (n = 3/section; 3 sections analyzed/animal).
KrasG12D; Trp53R172H; 
Pdx1-Cre (n=60)
Caerulein only:
daily i.p. injection 
of 5µg caerulein from 
9th week of life
(n=16)
Gemcitabine only:
2.5mg gemcitabine weekly
from 13th week of life
(n=12)
Control group:
daily i.p.
0.9% saline injection
from 9th week of life
(n=16)
Caerulein+gemcitabine:
daily i.p. injection 
of 5µg caerulein from 
9th week of life
+
2.5mg gemcitabine weekly 
from 13th week of life
(n=16)
Figure 1. Study design of the LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre transgenic mice.
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A portion of fresh tumor tissue was homogenized and lysed with
600-μl buffer RLT, and whole RNAwas extracted using the RNeasy kit
(Qiagen, Hilden, Germany) with on-column DNA digestion following
the standard protocol provided by the manufacturer. The mRNA was
reverse transcribed into cDNA with oligo-dT primers using the
Superscript 1st Strand System for reverse transcription-PCR (Invitro-
gen, Carlsbad, CA, USA) at 42°C for 50minutes. All PCRs were carried
out on a 7500 Real-Time PCR System (Applied Biosystems, Foster
City, CA). Following an activation step at 95°C for 10 minutes,
determination of mRNA expression was performed over 40 cycles with
15 seconds of denaturation at 95°C and annealing/extension/data
acquisition at 60°C for 60 seconds using the Power SYBR Green PCR
kit (Applied Biosystems). Primer sequences are available on
request. Relative fold mRNA expression levels were determined using
the 2(−ΔΔCt) method. All reactions were performed in triplicates, and
results are presented as means and standard errors.
Serum Analysis of mIL-1α, mIL-6, CRP, mIL-10,
Interferon-γ, and Macrophage Inflammatory Protein-1α
The serum drawn from mice at the time of sacrifice was tested in
commercial ELISA tests specifically according to the recommenda-
tions by the manufacturer (BD Biosciences Cell Analysis, Heidelberg,
Germany) for mIL-1α, mIL-6, CRP, mIL-10, interferon-γ, and
macrophage inflammatory protein-1α. The ELISA plate was
measured on an Emax plate reader (Molecular Devices) and analyzed
with SOFTmax Pro (Version 3-0) software.
STAT3 Phosphorylation of PDAC Cells In Vitro
Equal numbers of human Paca44 PDAC cells were seeded into six-
well plates and allowed to adhere overnight. Subsequently, the
subconfluent cells were washed with PBS and cultured in 0.5% FBS
containing growth medium (DMEM, high glucose including sodium
pyruvate, penicillin/streptomycin) plus/minus 1 μM gemcitabine
plus/minus recombinant human IL-6 (20 ng/ml; Sigma-Aldrich) for
72 hours. Subsequently, the low-serum–containing medium was
removed, and cells were cultured in full growth medium containing
10% FBS plus/minus IL-6 (20 ng/ml) for 6 days. Finally, cells were
trypsinized, and cell numbers were determined by automated cell
counting. Raw values were normalized to untreated controls. Bars
represent mean values of normalized values +/− SD.Statistical Analysis
Survival curves were computed using the Kaplan-Meier method.
Log-rank test was applied to identify significant differences.
Differences in the mean of two samples were analyzed by an
unpaired t test. Comparisons of more than two groups were made by
a one-way analysis of variance with post hoc Holm-Šidák analysis for
pair-wise comparisons and comparisons versus control and by
Kruskal-Wallis one-way analysis of variance. P values b .05 were
considered statistically significant. Data were analyzed using SPSS
software (Version 14; SPSS, Inc., Chicago, IL).
Results
Development of Pancreatic Cancer in LSL-KrasG12D;
LSL-Trp53R172H; Pdx1-Cre mice
As previously described in the initial reports [21,23] and by our
group [22], we observed development of fully invasive pancreatic
cancers in LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre transgenic
mice. The histology resembled ductal adenocarcinomas of the
pancreas or its precursor lesions observed in humans.
As expected by the nature of the study design, where survival was
defined as the major endpoint, all mice developed fully invasive
pancreatic cancer (Figure 2A–D). We did not find any histopatho-
logic differences in the four groups. Furthermore, we found no
differences of expression of amylase as a marker of exocrine
compartment (Figure 2E–H) or in Masson’s trichrome in between
the cohorts (Figure 2I–L).
Induction of Systemic Inflammatory Response Syndrome and
Mild Chronic Pancreatitis in Caerulein-Treated LSL-KrasG12D;
LSL-Trp53R172H; Pdx1-Cre mice
To obtain mild chronic pancreatitis, caerulein was injected as
described above. In contrast to the control group (data not shown) and
the mono-gemcitabine-treated mice (Figure 3A), all caerulein-treated
animals developed the typical changes of mild chronic pancreatitis
marked by a massive infiltration of lymphocytes (Figure 3B).
The serum ELISA tests for mIL-6 (Figure 3C), mIL-1α
(Figure 3D), and mCRP (Figure 3E) were performed at the day
of euthanization and proved the systemic inflammatory response
syndrome in the mice by measuring significantly elevated serum levels
for these three markers in both caerulein-treated groups compared to
A DCB
HGFE
LKJI
Amylase
H&E H&E H&E H&E
AmylaseAmylaseAmylase
Masson’s Masson’sMasson’s Masson’s
Figure 2.Development of pancreatic cancer in LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cremice. All mice developed fully invasive pancreatic
cancer.Wedidnot find anyhistopathologic differences in the four groups (A–D) H&E, 10×. Furthermore,wedidnot finddifferences in expression
of amylase (10×) as a marker of exocrine compartment (E–H) or in Masson’s trichrome (10×) in between the cohorts (I–L).
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contrast, IL-10, interferon-γ and macrophage inflammatory protein-
1α serum levels were not significantly elevated (data not shown).
Expression of Nuclear Factor-κΒ (NF-κB), IL6, and p-STAT3
in LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre-derived mice
After proving the induction of a mild chronic pancreatitis, we sought
to evaluate the differences of expression of IL-6, p-STAT3, and NF-κB
in the four different groups by immunohistochemistry (Figure 4).
IL-6 and NF-κB were widely expressed in all four groups
(Figure 4A–D and I–L) without showing any significant differences.
In contrast, p-STAT3 was expressed significantly higher in both
groups treated with caerulein (Figure 4F and H) compared to the
control group or the monogemcitabine group (Figure 4E and G).
Systemic Inflammatory Response Syndrome Diminishes the
Beneficial Survival Effects of Gemcitabine in LSL-KrasG12D;
LSL-Trp53R172H; Pdx1-Cre Mice
As expected, intraperitoneal application of gemcitabine increased
median survival of LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre mice
compared to mock-treated animals (median survival 191 vs 121 days;
P b .05; Figure 5). Induced systemic inflammatory response syndrome
diminished the beneficial effects of gemcitabine upon median overall
survival. Inmedian, the caerulein-plus-gemcitabine group survived only
127 days, which was significantly less compared to the monogemci-
tabine group (P = .023). The caerulein-mono group survived 114 days.
Sonic Hedgehog (Shh) and Nestin Expression in LSL-
KrasG12D; LSL-Trp53R172H; Pdx1-Cre Mice
Because our group previously has shown that both the hedgehog
pathway and the exocrine progenitor marker nestin are activated inpancreatic injury and regeneration, we wanted to evaluate the
expression of both markers in the four groups. Interestingly, we
observed a stronger expression of the hedgehog ligand sonic in the
stroma of mice treated with caerulein only (Figure 6B) compared to
the other three groups (Figure 6A, C, and D). The same expression
pattern was found for nestin, where we observed a widespread
upregulation in the mesenchymal periacinar cells in the group treated
with caerulein only (Figure 6F).
IL-6 Promotes PDAC Cell Survival During
Gemcitabine Treatment
To recapitulate our in vivo findings in a controlled environment,
we turned to cultured PDAC cells. When human Paca44 cells were
grown in culture, additionally added recombinant IL-6 had a
negligible effect on their growth despite the fact that they were
responsive to the recombinant protein (Figure 6I and inset). On the
contrary, exogenous IL-6 significantly increased the cell number in
the presence of gemcitabine when compared to the treatment with
gemcitabine alone. Taken together, these findings suggest that the cell
growth and/or survival–promoting effects of IL-6 become most
evident under conditions of cellular stress.
Discussion
The conditional LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre
mice express endogenous mutant Kras and p53 alleles in pancreatic
cells and develop metastatic PDAC that recapitulates the human
spectrum [21,23]. The use of these models provides now the
opportunity to conduct chemopreventive [22] or chemotherapeutic
as well as imaging [25] studies on pancreatic cancer. Using this
genetically engineered mouse model of PDAC, we could now
demonstrate for the first time that the impact of chemotherapy with
CRP (ng/ml)
p=0.045*
p=0.002*
2
Interleukin-1α (ng/ml)
p=0.028*
p=0.008*
3
Interleukin-6 (ng/ml)
p=0.029*
p=0.096
A B
C
D E
H&E H&E
Figure 3. Mild pancreatitis and systemic inflammatory response syndrome. In contrast to the control group (data not shown) and
mice treated with gemcitabine only (A), all caerulein-treated animals developed the typical changes of mild chronic pancreatitis marked by
a massive infiltration of lymphocytes (B). H&E, 20×. The serum ELISA tests for mIL-6 (C), mIL-1α (D), and mCRP (E) proved the systemic
inflammatory response syndrome in the mice by measuring significantly elevated serum levels for these three markers in both caerulein-
treated groups compared to the control group and monogemcitabine group.
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pancreatitis and a systemic inflammatory response syndrome. To
understand the idea of this study, we had to take a step back from
bedside to bench.
Several clinical studies have shown for years that the presence of
elevated CRP levels is a negative prognostic factor for patients with
PDAC. Some years ago, a study showed that, in patients who have
undergone potentially curative resection for PDAC, the presence of a
systemic inflammatory response predicts poor outcome. Those
patients with a postoperative CRP b10 mg/l had a median survival
of 21.5 months compared with only 8.4 months in those patients
with a CRP N10 mg/l (P = .001). Interestingly, patients with an
elevated CRP had more vascular invasion and had poorer tumor
differentiation [26]. Drawing the comparison to our study, the results
from Nakachi et al., were very interesting. The authors identified
patients with gemcitabine-refractory disease by univariate and
multivariate analyses and found low performance status, peritoneal
dissemination, and elevated CRP level to be individual risk factors.
Median survival time in patients with a CRP level of b5.0 mg/dl was
2.4 months, which was significantly better than the 1.4 months for
patients with CRP levels of N5.0 mg/dl [27]. In a study from Sweden
[28], 119 consecutive patients with PDAC receiving palliativechemotherapy with gemcitabine were analyzed regarding predictive
factors of survival. The overall median survival was 4.4 months. By
means of a multivariate analysis, it was shown that CRP (P b .001)
was an independent predictor of survival. The median survival of
patients with normal CRP at the time of diagnosis was 10.8 months
versus only 4.2 months for those with raised CRP levels (≥ = 5 mg/l;
P b .001). In our study, having in mind all the difficulties of
comparing mice and men, a systemic inflammatory response
syndrome induced by a mild chronic pancreatitis diminished the
beneficial effects of gemcitabine upon median overall survival. In
median, the monogemcitabine group survived 191 days, whereas the
caerulein–gemcitabine group survived only 127 days (P b .05) and
was in the same range as the caerulein-mono group and the control
group.When the pancreata of the mice were resected and analyzed
(Figure 2A–D), virtually no acinar tissue was left, leaving the
question of how long during the caerulein treatment can acinar
cells contribute to induce pancreatitis. In a very elegant study by
Guerra et al. [29], they found that, after 3 months of caerulein
treatment with the same protocol as we used in our study, mice
displayed atrophic acini in about 20% and all characteristics of
chronic pancreatitis. At 5 months of age, pancreata of mice
displayed more severe acinar atrophy and increased fibrosis
A DCB
HGFE
K LJI
Il-6
NF-κB 
Il-6Il-6Il-6
NF-κB NF-κB NF-κB 
p-STAT3 p-STAT3 p-STAT3 p-STAT3 
Figure 4. Immunohistochemistry for IL-6, NF-κB, and p-STAT3. IL-6 and NF-κB were widely expressed in all four groups (A–D and I–L)
without showing any significant differences. In contrast, p-STAT3 was significantly higher expressed in groups treated with caerulein only or
with gemcitabine and caerulein, respectively (F andH), compared to the control group ormice treatedwith gemcitabine alone (E andG), 40×.
468 Inflammation and chemotherapy in pancreatic cancer Knoop et al. Neoplasia Vol. 16, No. 6, 2014beside invasive PDAC. Because, in our study, the mean survival
was between 127 and 191 days, we can assume that chronic
pancreatitis was maintained shortly before death of the mice.
To recapitulate our in vivo findings in a controlled environment,
we turned to cultured PDAC cells. We found that exogenous IL-6
significantly increased the cell number in the presence of gemcitabineFigure 5. Systemic inflammatory response syndrome dimin-
ishes survival. Kaplan-Meier survival curve shows a prolonged
overall median survival of LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre
mice treated with gemcitabine alone compared to mock-treated
animals (median survival 191 vs 121 days; P b .05). Induced
systemic inflammatory response syndrome diminished the bene-
ficial effects of gemcitabine upon median overall survival. In
median, the caerulein-plus-gemcitabine group survived only 127
days, which was significantly less compared to the gemcitabine
group (P = .023). The caerulein-mono group survived 114 days.when compared to the treatment with gemcitabine alone. This led us
to the conclusion that the cell growth and/or survival–promoting
effects of IL-6 become most evident under conditions of cellular stress
and may be an explanation for the lost impact of gemcitabine in our
in vivo study. So, we next sought to evaluate the IL-6 levels in our
treated mice. And indeed, we could measure significantly elevated
serum levels for IL-6, IL-1α, and mCRP in mice treated with
caerulein or caerulein plus gemcitabine compared to the control
group or the monogemcitabine group. Because it is well known that
STAT3 leads to a production of IL-6, we next evaluated the p-STAT3
levels in our resected pancreatic specimen.
In PDACs, constitutive activation of STAT3 by phosphorylation
of Tyr705 has been reported in 30% to 100% of human tumor
specimens, as well as in many PDAC cell lines [30,31]. By contrast,
this pathway is inactive in the normal pancreas, and correspondingly,
STAT3 is not required for pancreatic development or homeostasis, as
shown by conditional knockout studies in mice [32]. It has been
shown that STAT3 is required for the process of acinar-to-ductal
metaplasia (ADM) upon ectopic expression of Pdx-1 [33]. Very
recently, three elegant studies revealed the role of STAT3 in
pancreatic tumorigenesis. By using the same transgenic mouse
model as we did in our study, Corcoran et al., showed that STAT3 is
required for the development of the earliest premalignant pancreatic
lesions, ADM, and PanINs. Moreover, acute STAT3 inactivation
blocked PDAC initiation in an orthotopic mouse model [19]. Two
current papers demonstrate that STAT3 activation is essential for
initiation and progression of PDAC [34,35]. Using the same mouse
model as we did, STAT3 in pancreatic epithelial cells promotes
tumor development and progression, as its ablation resulted in smaller
lesions, lower tumor grade, and fewer metastases. Importantly, both
groups demonstrate that STAT3 ablation in pancreatic epithelial
cells attenuates KrasG12D-induced PanIN formation, concluding
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[34,35]. Interestingly, we found a significantly higher expression of
p-STAT3 in groups treated with caerulein only or with gemcitabine
and caerulein compared to the control group or the monogemcita-
bine group, a fact that is in line with very recent results from other
groups [36]. Fukuda et al., found that STAT3 in pancreatic cells
directly affects expression of IL-6 and IL-1, both of which are
STAT3-activating cytokines [34]. This could be the reason for the
elevated serum levels of IL-6 and IL-1α in our caerulein-treated mice.
Equally important is STAT3’s ability to promote conversion of
quiescent adult pancreatic epithelial cells to cells with a progenitor-
like phenotype upon pancreatitis or other insults [34], a process often
referred to as ADM. As a result of ADM, more ductal cells expressing
progenitor cell markers, such as Pdx-1 or Shh, are formed, and these
cells are more susceptible to Kras-mediated transformation [37,38].
Because our group previously has shown that both the hedgehog
pathway and the exocrine progenitor marker nestin are activated in
pancreatic injury and regeneration [38], we wanted to evaluate the
expression of both markers in the four groups. Interestingly, we
observed a stronger expression of the hedgehog ligand sonic in thestroma of mice treated with caerulein only compared to the other
three groups. The same expression pattern was found for nestin,
where we observed a widespread upregulation in the mesenchymal
periacinar cells in the group treated with caerulein only. Both
markers, especially the expression of the hedgehog ligand, may also
contribute to further chemoresistance as shown by Olive et al. [20].
Which clinical impact may our preclinical study have? Unlike in
advanced colorectal and hepatocellular malignancies, biologic agents
have not had success in the treatment of advanced pancreatic cancer.
Many patients are suitable only for palliative treatment at time of
diagnosis. The decision of how aggressively to treat these patients is
often difficult and depends on a number of factors, including age,
medical comorbidity, cancer staging, patient preference, and local
expertise. Unfortunately, in many cases, individual prognosis is
unclear, and decision making can be highly subjective. Therefore,
there is an important clinical requirement to select patients with
biologically aggressive pancreatic cancer and to tailor both nonsurgical
and surgical therapy using novel tumor- and host-based markers. In
light of the mentioned clinical studies above [26–28], there is
considerable interest in the systemic inflammatory response as a
470 Inflammation and chemotherapy in pancreatic cancer Knoop et al. Neoplasia Vol. 16, No. 6, 2014prognostic factor in the cancer patient. We feel that our results
strengthen these clinical observations made by these groups. In
particular, the inflammation serum biomarkers CRP, IL-6, and IL-1α
could indicate the prognostic benefit of gemcitabine chemotherapy
and should now be tested in prospective patient-controlled trials.
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